GET DAILY SIGNALSIDXX Could Advance +11% Toward $780 Analyst Target
Key Takeaways
- The $780 level represents the average of four verified analyst price targets sitting above the current share price, showing how far bullish analysts believe IDEXX Laboratories (IDXX) can rise.
- IDXX closed at $702.59 on November 11, 2026, so the stock would need roughly an 11% gain to hit that mark.
- Those four above-price targets range from $750 to $810; the broader mean of all tracked targets sits near $717, with a full spread from about $470 to $810.
- A strong third-quarter earnings beat and raised guidance stand out as the main drivers behind recent target increases.
- Key risks include a premium valuation, uneven veterinary-visit trends, and a wide analyst range that highlights real differences of opinion on growth sustainability.
- Track updates on the stock's Major News, Today's Price Move, Forecast, and Earnings pages.
Understanding the Analyst Targets
IDEXX Laboratories (IDXX) is a Westbrook, Maine-based company focused on veterinary diagnostics and software for companion animals, livestock, and water testing. The overall mean of all current targets sits near $717 across 14 analysts, less than 10% above the latest price. The $780 figure comes from averaging only the verified targets that remain above the current level: Morgan Stanley at $810 (Buy, November 3, 2026), Jefferies at $770 (Buy, November 3, 2026), J.P. Morgan at $750 (Overweight, October 16, 2026), and Bank of America Securities at $790 (Hold). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The full analyst range remains unusually wide, from roughly $470 to $810, which points to meaningful disagreement. Bullish views focus on recurring diagnostics revenue and an innovation pipeline, while more cautious ones note the premium multiple offers little margin if demand weakens. That spread itself provides important context: the $780 level captures the optimistic end of Street thinking rather than a single published consensus.
Current Position and Path to the Target
IDXX finished at $702.59 on November 11, 2026. Reaching $780 would mean an advance of about 11%, a notable but achievable move. The stock jumped more than 20% on November 2 after reporting third-quarter EPS of $4.01 versus expectations near $3.71, then consolidated between roughly $670 and $710. With a P/E near 47 and market capitalization around $55 billion, further gains will depend more on delivering expected earnings growth than on any re-rating.
Factors That Could Support Further Gains
The recurring diagnostics business remains the core strength, producing predictable revenue from an expanding base of instruments. Management raised its 2025 outlook to roughly $4.27–$4.30 billion in revenue and EPS of about $12.81–$13.01, pointing to double-digit reported EPS growth. Analysts who raised targets after the report highlighted stronger U.S. and international companion-animal diagnostics, resilient pricing, and newer offerings such as cancer diagnostics. A premium valuation, ongoing share repurchases, and high returns on capital continue to appear in supportive research notes.
Risks That Could Limit Upside
Valuation stands as the main concern. At a P/E near 47, the stock already prices in durable above-market growth, so any sign of slowing momentum could pressure the multiple even if earnings align with forecasts. Veterinary-clinic visit trends have stayed uneven, and some analysts note that the newest analyzer, inVue Dx, may add meaningfully to recurring revenue only later. The wide target range, including a bearish estimate near $470, shows not every firm expects growth to continue at its recent pace. Insider selling or slower demand would add further pressure.
Technical Levels Worth Watching
The 52-week range of $500.61 to $769.98 offers useful perspective. The prior high of $769.98 sits almost exactly at the $780 target, creating a natural resistance zone. A decisive move above the $770–$780 area would mark a breakout to new highs, while failure to hold could turn it into resistance. Near-term support lies in the $670–$680 zone where shares consolidated after the post-earnings move, with deeper support near $650.
Time Horizon and Key Items to Monitor
Analyst targets generally reflect a roughly 12-month horizon, though the exact timeframe varies. Investors should follow the next earnings release, currently estimated for early February 2027, along with any guidance updates and growth in the installed base and recurring diagnostics revenue. Shifts in analyst targets, veterinary-visit data, and the inVue Dx launch trajectory remain the most relevant indicators.
Using AI Tools in My Research
Tickeron's AI Daily Buy/Sell Signals help me monitor stocks like IDXX by applying artificial intelligence to thousands of names and generating Buy, Sell, or Hold signals based on technical behavior and market conditions. I find these signals useful for spotting shifts after events like earnings without relying solely on manual chart review.
Final Assessment
Whether IDXX reaches $780 hinges on execution more than re-rating. The target averages four above-price analyst estimates ($750–$810) and would require about an 11% gain from $702.59. Strong supports include the earnings beat, raised guidance, and recurring-revenue durability, while the main hurdles are the premium valuation, uneven visit trends, and wide analyst spread. Because $780 aligns closely with the 52-week high, it also serves as a key technical test. No outcome is assured, so monitoring earnings, guidance, and analyst revisions remains essential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
IDXX in +5.36% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDXX advanced for three days, in 178 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 53 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 97 of 171 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.027) is normal, around the industry mean (67.298). P/E Ratio (47.242) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties
Advertisement